SALT LAKE CITY, March 5, 2014 (GLOBE NEWSWIRE) -- ARUP Laboratories announced on Monday, March 3, that it has added the Prosigna Breast Cancer Prognostic Gene Signature assay to its comprehensive suite of breast cancer diagnostic tests. This assay is FDA 510(k) cleared for node-negative (stage I or II) or node-positive (stage II), hormone receptor-positive (HR+) breast cancer patients.
Prosigna provides an individualized assessment of a patient's risk of recurrence at 10 years given endocrine therapy alone. The test uses the biology of the tumor and clinical variables to assess risk and has shown improved prognostic accuracy over other breast cancer tests on the market.
"This is the next generation of diagnostics, which embraces both the molecular and anatomic features of a tumor to provide a more accurate estimate of risk," said Philip Bernard, MD, ARUP Laboratories' medical director and associate professor in the Department of Pathology at the University of Utah.
The University of Utah and the Huntsman Cancer Institute in Salt Lake City were integral in developing the 50-gene expression signature. Dr. Philip Bernard, a co-inventor of the test and medical director of molecular oncology diagnostics at ARUP Laboratories, oversees the test and can provide additional consultation through ARUP Client Services.
Visit ARUP's Prosigna page for further information.
About ARUP Laboratories
Founded in 1984, ARUP Laboratories is a leading national reference laboratory and a nonprofit enterprise of the University of Utah and its Department of Pathology. ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. ARUP serves clients across the United States, including many of the nation's top university teaching hospitals and children's hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and other government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology®.
CONTACT: Vanna Livaditis (801) 583-2787, ext. 3635 email@example.comSource:ARUP Laboratories